Endocrinology

Top Story

RYGB-induced weight loss alters postprandial FGF21 metabolism

RYGB-induced weight loss alters postprandial FGF21 metabolism
August 18, 2017

Postprandial fibroblast growth factor 21 metabolism is uniquely affected by Roux-en-Y gastric bypass-induced weight loss, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Samuel Klein, MD, of the Center for Human Nutrition at Washington University School of Medicine in St. Louis, and colleagues evaluated adults with obesity who underwent Roux-en-Y gastric bypass (RYGB; n = 16) or laparoscopic adjustable gastric band (LAGB; n = 12) to determine whether weight loss induced by surgery increases postprandial plasma fibroblast growth factor 19 (FGF19) and FGF21 concentrations.

In the Journals Plus

Hyperglycemia, insulin resistance tied to low trabecular bone score in older men

August 18, 2017
Japanese men with hyperglycemia and higher levels of insulin resistance are more likely to have a lower trabecular bone score than men who are not insulin resistant…

Biocept, UT Southwestern to study liquid biopsy platform in ALK-positive non-small cell lung cancer

August 18, 2017
Biocept Inc. and University of Texas Southwestern Medical Center entered a clinical study agreement to evaluate the clinical utility of Biocept’s Target Selector…
In the Journals Plus

IV to subcutaneous insulin transition rate low in ICU

August 18, 2017
Rates of transition from IV insulin infusion to subcutaneous insulin were low in an ICU setting, according to researchers from Cleveland Clinic. Their findings highlight
In the Journals Plus

Adverse metabolic outcomes evident in infants of nulliparous women

August 18, 2017
Infants born to nulliparous women with overweight or obesity compared with those born to multiparous women are exposed to a less favorable metabolic environment in utero…
More Headlines »
CME CNE CE CE

Diabetic Retinopathy: Preferred Practice Patterns in Screening and Management

This activity is supported by an educational grant from Regeneron.

Diabetic retinopathy (DR) is a major cause of blindness among American adults aged 40 years and older. The prevalence…
More »
Video
Meeting News

VIDEO: Certain antiplatelet therapies more beneficial for patients with vs. without diabetes

July 15, 2017
More »
Resource Centers
CME

Obesity Consults® ObesityForum® 2015 Highlights

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Novo Nordisk, Inc.

Obesity has increased dramatically in the past 20 years and is considered a health care epidemic in the United States…
More »
Current Issues
View the Current Issue
Advertisement
Advertisement